US Pharma MarketingThe latest agreement includes higher fees for overseas firms, hiring transparency requirements and greater use of real-world evidence.
Device firms back latest MDUFA deal, while patients want more postmarket safety
Device firms back latest MDUFA deal, while patients want more postmarket safety is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: MedTech Dive